ID   SCCIC19
AC   CVCL_VJ53
SY   SCC IC19; IC9
DR   cancercelllines; CVCL_VJ53
DR   CancerTools; 153671
DR   Cosmic; 2688666
DR   GEO; GSM2611500
DR   GEO; GSM2611501
DR   GEO; GSM2611502
DR   Wikidata; Q98129375
DR   Ximbio; 153671
RX   PubMed=24662767;
RX   PubMed=30202019;
RX   PubMed=31336867;
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>A; ClinVar=VCV000635365; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys254Arg (c.760T>C); ClinVar=VCV002130225; Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Trp1843Ter (c.5528G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys315Ter (c.945T>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro64Leu (c.191C>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Glu (c.596G>A); ClinVar=VCV000582257; Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=24662767).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Scalp, skin; UBERON=UBERON_8300000.
ST   Source(s): PubMed=31336867
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 10,12
ST   D16S539: 9,12
ST   D18S51: 11,18
ST   D19S433: 13.1,15.2
ST   D21S11: 32.2
ST   D2S1338: 19,21
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 13,15
ST   FGA: 20,22
ST   TH01: 6,7
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   81Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 30-01-24; Version: 11
//
RX   PubMed=24662767; DOI=10.1038/jid.2014.154; PMCID=PMC4753672;
RA   South A.P., Purdie K.J., Watt S.A., Haldenby S., den Breems N.Y.,
RA   Dimon M., Arron S.T., Kluk M.J., Aster J.C., McHugh A., Xue D.J.,
RA   Dayal J.H.S., Robinson K.S., Rizvi S.M.H., Proby C.M., Harwood C.A.,
RA   Leigh I.M.;
RT   "NOTCH1 mutations occur early during cutaneous squamous cell
RT   carcinogenesis.";
RL   J. Invest. Dermatol. 134:2630-2638(2014).
//
RX   PubMed=30202019; DOI=10.1038/s41467-018-06027-1; PMCID=PMC6131170;
RA   Inman G.J., Wang J., Nagano A., Alexandrov L.B., Purdie K.J.,
RA   Taylor R.G., Sherwood V., Thomson J., Hogan S., Spender L.C.,
RA   South A.P., Stratton M.R., Chelala C., Harwood C.A., Proby C.M.,
RA   Leigh I.M.;
RT   "The genomic landscape of cutaneous SCC reveals drivers and a novel
RT   azathioprine associated mutational signature.";
RL   Nat. Commun. 9:3667.1-3667.14(2018).
//
RX   PubMed=31336867; DOI=10.3390/ijms20143428; PMCID=PMC6678499;
RA   Hassan S., Purdie K.J., Wang J., Harwood C.A., Proby C.M.,
RA   Pourreyron C., Mladkova N., Nagano A., Dhayade S., Athineos D.,
RA   Caley M., Mannella V., Blyth K., Inman G.J., Leigh I.M.;
RT   "A Unique panel of patient-derived cutaneous squamous cell carcinoma
RT   cell lines provides a preclinical pathway for therapeutic testing.";
RL   Int. J. Mol. Sci. 20:3428.1-3428.26(2019).
//